474 related articles for article (PubMed ID: 16304358)
21. A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-thalassemia gene therapy.
Li W; Xie S; Guo X; Gong X; Wang S; Lin D; Zhang J; Ren Z; Huang S; Zeng F; Zeng Y
Haematologica; 2008 Mar; 93(3):356-62. PubMed ID: 18268280
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Mono- and Bi-Functional GLOBE-Based Vectors for Therapy of β-Thalassemia by
Koniali L; Flouri C; Kostopoulou MI; Papaioannou NY; Papasavva PL; Naiisseh B; Stephanou C; Demetriadou A; Sitarou M; Christou S; Antoniou MN; Kleanthous M; Patsali P; Lederer CW
Cells; 2023 Dec; 12(24):. PubMed ID: 38132168
[TBL] [Abstract][Full Text] [Related]
23. Gene therapy for hemoglobinopathies: the state of the field and the future.
Chandrakasan S; Malik P
Hematol Oncol Clin North Am; 2014 Apr; 28(2):199-216. PubMed ID: 24589262
[TBL] [Abstract][Full Text] [Related]
24. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
Dong AC; Rivella S
Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
[TBL] [Abstract][Full Text] [Related]
25. Reducing the transcriptional read-through rate of a lentiviral vector for β-thalassemia gene therapy.
Wu J; Chen Y; Shen W; Zhang J; Zeng F
J Gene Med; 2024 Jan; 26(1):e3640. PubMed ID: 37989259
[TBL] [Abstract][Full Text] [Related]
26. Advances in stem cell transplantation and gene therapy in the β-hemoglobinopathies.
Payen E; Leboulch P
Hematology Am Soc Hematol Educ Program; 2012; 2012():276-83. PubMed ID: 23233592
[TBL] [Abstract][Full Text] [Related]
27. Engineered U7 snRNA mediates sustained splicing correction in erythroid cells from β-thalassemia/HbE patients.
Preedagasamzin S; Nualkaew T; Pongrujikorn T; Jinawath N; Kole R; Fucharoen S; Jearawiriyapaisarn N; Svasti S
Biochem Biophys Res Commun; 2018 Apr; 499(1):86-92. PubMed ID: 29550480
[TBL] [Abstract][Full Text] [Related]
28. Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region.
Arumugam PI; Higashimoto T; Urbinati F; Modlich U; Nestheide S; Xia P; Fox C; Corsinotti A; Baum C; Malik P
Mol Ther; 2009 Nov; 17(11):1929-37. PubMed ID: 19707188
[TBL] [Abstract][Full Text] [Related]
29. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
Magrin E; Miccio A; Cavazzana M
Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
[TBL] [Abstract][Full Text] [Related]
30. A preclinical approach for gene therapy of beta-thalassemia.
Breda L; Kleinert DA; Casu C; Casula L; Cartegni L; Fibach E; Mancini I; Giardina PJ; Gambari R; Rivella S
Ann N Y Acad Sci; 2010 Aug; 1202():134-40. PubMed ID: 20712784
[TBL] [Abstract][Full Text] [Related]
31. Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathies.
Breda L; Ghiaccio V; Tanaka N; Jarocha D; Ikawa Y; Abdulmalik O; Dong A; Casu C; Raabe TD; Shan X; Danet-Desnoyers GA; Doto AM; Everett J; Bushman FD; Radaelli E; Assenmacher CA; Tarrant JC; Hoepp N; Kurita R; Nakamura Y; Guzikowski V; Smith-Whitley K; Kwiatkowski JL; Rivella S
Mol Ther; 2021 Apr; 29(4):1625-1638. PubMed ID: 33515514
[TBL] [Abstract][Full Text] [Related]
32. Gene specificity of suppression of transgene-mediated insertional transcriptional activation by the chicken HS4 insulator.
Desprat R; Bouhassira EE
PLoS One; 2009 Jun; 4(6):e5956. PubMed ID: 19536296
[TBL] [Abstract][Full Text] [Related]
33. Towards β-globin gene-targeting with integrase-defective lentiviral vectors.
Inanlou DN; Yakhchali B; Khanahmad H; Gardaneh M; Movassagh H; Cohan RA; Ardestani MS; Mahdian R; Zeinali S
Biotechnol Lett; 2010 Nov; 32(11):1615-21. PubMed ID: 20640481
[TBL] [Abstract][Full Text] [Related]
34. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.
Rivella S; May C; Chadburn A; Rivière I; Sadelain M
Blood; 2003 Apr; 101(8):2932-9. PubMed ID: 12480689
[TBL] [Abstract][Full Text] [Related]
35. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.
Segura EER; Ayoub PG; Hart KL; Kohn DB
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992422
[TBL] [Abstract][Full Text] [Related]
36. A New Era for Hemoglobinopathies: More Than One Curative Option.
Psatha N; Papayanni PG; Yannaki E
Curr Gene Ther; 2017; 17(5):364-378. PubMed ID: 29357790
[TBL] [Abstract][Full Text] [Related]
37. Development of viral vectors for gene therapy of beta-chain hemoglobinopathies: optimization of a gamma-globin gene expression cassette.
Li Q; Emery DW; Fernandez M; Han H; Stamatoyannopoulos G
Blood; 1999 Apr; 93(7):2208-16. PubMed ID: 10090929
[TBL] [Abstract][Full Text] [Related]
38. Therapy for beta-globinopathies: a brief review and determinants for successful and safe correction.
Perumbeti A; Malik P
Ann N Y Acad Sci; 2010 Aug; 1202():36-44. PubMed ID: 20712770
[TBL] [Abstract][Full Text] [Related]
39. Current status of globin gene therapy for the treatment of beta-thalassaemia.
Lisowski L; Sadelain M
Br J Haematol; 2008 May; 141(3):335-45. PubMed ID: 18410569
[TBL] [Abstract][Full Text] [Related]
40. Hemoglobin gene therapy for β-thalassemia.
Bank A
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1187-201. PubMed ID: 21075288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
